Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrazione
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MEI PHARMA, INC.

(MEIP)
  Rapporto
Tempo differito Nasdaq  -  22:00 23/09/2022
0.4153 USD   -1.33%
22/09Mei Pharma annuncia cambiamenti nel Consiglio di Amministrazione
CI
15/09MEI Pharma, Inc. annuncia cambiamenti nel Consiglio di Amministrazione
CI
08/09MEI Pharma, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 30 giugno 2022
CI
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su MEI PHARMA, INC.
22/09MEI Pharma Announces Changes to Board of Directors
22/09Mei Pharma Announces Changes to Board of Directors
19/09MEI PHARMA, INC.(NASDAQCM: MEIP) dropped from S&P Global BMI Index
15/09MEI PHARMA, INC.: Change in Directors or Principal Officers (form 8-K)
15/09MEI Pharma, Inc. Announces Board Changes
08/09TRANSCRIPT: MEI Pharma, Inc., 2022 Earnings Call, Sep 08, 2022
08/09MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights
08/09MEI PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Resul..
08/09MEI Pharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022
08/09NORTH AMERICAN MORNING BRIEFING: Futures Edge -2-
06/09MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2..
02/09MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
01/09MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01/09MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Upda..
02/08MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
01/08MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
18/07MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Pha..
18/07MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Pha..
07/07MEI PHARMA, INC.: Change in Directors or Principal Officers, Financial Statements and Exh..
04/07MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
01/07MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
30/06Fate Therapeutics Appoints Brian Powl as Chief Commercial Officer
22/06MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer
22/06MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer
10/06MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology As..
04/06MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society o..
04/06MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society o..
02/06MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
01/06MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26/05MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the Amer..
23/05MEI PHARMA: Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights - F..
23/05MEI Pharma Q3 Net Loss Narrows; Revenue Increases Almost 20%
23/05 MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights
23/05Earnings Flash (MEIP) MEI PHARMA Posts Q3 Revenue $9.7M
23/05MEI PHARMA, INC.: Management's Discussion and Analysis of Financial Condition and Results..
23/05MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended M..
23/05MEI PHARMA, INC.: Management's Discussion and Analysis of Financial Condition and Results..
23/05MEI PHARMA, INC. - 10-K/A - Management's Discussion and Analysis of Financial Condition..
19/05NORTH AMERICAN MORNING BRIEFING: Stocks Set for -2-
18/05MEI PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf..
17/05MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022
13/05MEI PHARMA, INC.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or S..
12/05MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the..
02/05MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08/04MEI Pharma Announces Two Presentations at the American Association for Cancer Research ..
04/04MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
01/04MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
25/03SECTOR UPDATE: Health Care Stock Edging Higher Near Friday Close
25/03Top Midday Decliners
25/03SECTOR UPDATE: Health Care Stocks Weakening in Afternoon Trading
25/03SECTOR UPDATE: Health Care
25/03Wall Street Set to Extend Gains After Jobless Claims Drop to Multi-Decade Low
25/03SECTOR UPDATE: Health Care Stocks Advance Pre-Bell Friday
25/03SECTOR UPDATE: Health Care
25/03Top Premarket Decliners
25/03MEI PHARMA: and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting wit..
25/03MEI PHARMA, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
24/03MEI Pharma to Delay Marketing Application For Zandelisib After FDA Mandates Randomized ..
24/03TRANSCRIPT: MEI Pharma, Inc. - Special Call
24/03MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting wi..
24/03MEI Pharma, Inc. and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meet..
16/03Developing Biopharma Plays to Look at Now (STAB, MEIP, ABIO, AMPE, ZIVO, MREO)
08/03MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Assoc..
07/03Certain Common Stock of MEI Pharma, Inc. are subject to a Lock-Up Agreement Ending on 7..
07/03Certain Restricted Stock Units of MEI Pharma, Inc. are subject to a Lock-Up Agreement E..
07/03Certain Options of MEI Pharma, Inc. are subject to a Lock-Up Agreement Ending on 7-MAR-..
07/03Certain Warrants of MEI Pharma, Inc. are subject to a Lock-Up Agreement Ending on 7-MAR..
02/03MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
01/03MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
11/02MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights
10/02Earnings Flash (MEIP) MEI PHARMA Posts Q2 Revenue $18.2M
10/02 MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights
10/02MEI PHARMA, INC.: Management's Discussion and Analysis of Financial Condition and Results..
10/02MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended D..
07/02MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointmen..
07/02MEI Pharma, Inc. Announces New Key Executive Appointments
02/02MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
01/02MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
10/01MEI PHARMA: January 2022 Corporate Presentation
03/01MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021MEI PHARMA, INC.: Change in Directors or Principal Officers, Financial Statements and Exh..
2021MEI PHARMA, INC.: Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submis..
2021TRANSCRIPT: MEI Pharma, Inc. - Shareholder/Analyst Call
2021MEI PHARMA: Announces Pricing of Public Offering of Common Stock - Form 8-K
2021MEI PHARMA, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
2021MEI Pharma Closes Common Stock Offering
2021MEI Pharma Announces Closing of Public Offering of Common Stock
2021MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
2021MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021MEI Pharma Prices Common Stock Offering at $2.60 Per Share
2021MEI Pharma Announces Pricing of Public Offering of Common Stock
2021MEI Pharma Plans Common Stock Offering -- Shares Climb After-Hours
2021MEI Pharma Announces Proposed Public Offering of Common Stock
2021MEI Pharma Shares Rise 22% After Positive Data for Zandelisib Trial
2021Health Care Stocks Mixed Ahead of Tuesday Opener
2021MEI Pharma Says Treatment With Follicular Lymphoma Drug Candidate Shows Complete Respon..
2021TRANSCRIPT: MEI Pharma, Inc. - Special Call
2021MEI PHARMA: and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Eva..
2021MEI PHARMA, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
2021MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Ev..